GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

By GSK’s reckoning, there are around 60,000 new cases of endometrial cancer diagnosed each year ... The launch environment for pharmaceutical industry products is evolving at pace with new ...

In weakly acid conditions, lipid A can be hydrolyzed to obtain monophosphoryl lipid A (MPL® [GSK and other]), a compound ... Here we describe cancer vaccine candidates using MPL adjuvant in ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK will also pay $70m to resolve a whistleblower complaint by a laboratory that alleged the drugmaker defrauded the US government by concealing Zantac's cancer ... that the products may contain ...